ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. oktober 22, 2024
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Press release Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome december 08, 2023
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. oktober 23, 2024
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. juni 28, 2022
ProQR to Participate in the Kempen Life Sciences Conference Press release … is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called … april 19, 2022
ProQR to Present at Upcoming Scientific Meeting and Investor Conference Press release … A presentation titled “Therapeutic RNA editing by Axiomer ® editing oligonucleotides” by Janne Turunen, PhD, … februari 06, 2018
ProQR to Webcast Virtual Analyst Event on November 18 Press release … to highlight its clinical stage pipeline programs and the Axiomer ® RNA editing platform. ProQR leadership will … november 11, 2021
ProQR Announces Expert Perspectives Conference Call Series Press release Initial call in the series will feature Usher syndrome and retinitis pigmentosa on June 22 juni 12, 2020